Journal of Thrombosis and Thrombolysis

, Volume 46, Issue 4, pp 466–472 | Cite as

Assessment of patients post reversal with idarucizumab

  • Veronica RacoEmail author
  • Tania Ahuja
  • David Green


Idarucizumab, a fully humanized Fab antibody fragment, is indicated for reversal of dabigatran’s anticoagulant activity. Idarucizumab neutralizes the anticoagulant effects of dabigatran by binding to dabigatran and its metabolite. In the full analysis of 503 patients, idarucizumab fully reversed the anticoagulant effect of dabigatran in more than 98% of patients. Real-world clinical experience with idarucizumab for dabigatran reversal remains limited. We report 11 real-world clinical cases in which idarucizumab was administered for dabigatran reversal in the setting of bleed (bleeding cohort n = 5) or emergent procedure (emergent procedure cohort, n = 6). Coagulation tests and clinical outcomes were assessed before and after idarucizumab administration. Clinical outcomes included thromboembolic events and hemostasis. The median (IQR) aPTT (seconds) before versus after idarucizumab was 40.4 (36.1) versus 27.3 (6.2) (bleeding cohort) and 50.1 (13.4) versus 26.5 (8.1) (emergent procedure cohort). The median (IQR) INR before and after idarucizumab was 2.0 (1.1) versus 1.2 (0.1) (bleeding cohort) and 1.1 (0.5) versus 1.1 (0.3) (emergent procedure cohort). Hemostasis was achieved in 4/5 patients in the bleeding cohort and 5/6 patients in the emergent procedure cohort. Thrombotic events occurred in four patients with a median time (IQR) from idarucizumab administration of 7.4 (4.3–14.7) days. Idarucizumab achieved adequate dabigatran reversal as evident by normalization of aPTT, INR, and achieving hemostasis. However, our data demonstrates a high thrombotic risk associated with dabigatran reversal with idarucizumab than previously reported.


Idarucizumab Dabigatran Reversal Thrombotic Hemostasis 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  2. 2.
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ Group R-CS (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352CrossRefPubMedGoogle Scholar
  3. 3.
    Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Investigators R-CIT (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772CrossRefPubMedGoogle Scholar
  4. 4.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363–2372CrossRefPubMedGoogle Scholar
  5. 5.
    PRAXBIND [Prescribing Information]. Ridgefield CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
  6. 6.
    Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554–3562CrossRefPubMedGoogle Scholar
  7. 7.
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127CrossRefPubMedGoogle Scholar
  8. 8.
    Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J (2015) Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386:680–690CrossRefPubMedGoogle Scholar
  9. 9.
    Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520CrossRefPubMedGoogle Scholar
  10. 10.
    Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI (2015) Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 114:198–205CrossRefPubMedGoogle Scholar
  11. 11.
    Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L et al (2017) Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 377(5):431–441CrossRefPubMedGoogle Scholar
  12. 12.
    Vosko MR, Bocksrucker C, Drwila R, Dulicek P, Hauer T, Mutzenbach J, Schlimp CJ, Spinler D, Wolf T, Zugwitz D (2017) Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb Thrombolysis 43:306–317CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ebinger J, Granger CB, Zhu A, Chang A, Henry TD (2017) Idarucizumab since FDA approval: use in the real-world. Am Heart J 193:93–94CrossRefPubMedGoogle Scholar
  14. 14.
    Rosenberg L, Gerstrom G, Nybo M (2017) Idarucizumab for reversal of dabigatran prior to acute surgery: a schematic approach based on a case report. Basic Clin Pharmacol Toxicol 120:407–410CrossRefPubMedGoogle Scholar
  15. 15.
    Braemswig TB, Eschenfelder CC, Nolte CH (2017) Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab. Am J Emerg Med 35:662 e3–e4CrossRefPubMedGoogle Scholar
  16. 16.
    Henderson RS Jr, Deshpande S, Williams B, Taylor BS, Tanaka KA (2017) Idarucizumab for dabigatran reversal in emergency type-a aortic dissection. J Cardiothorac Vasc Anesth 31:e80–e81CrossRefPubMedGoogle Scholar
  17. 17.
    Mazur P, Darocha T, Filip G, Grudzien G, Drwila R, Kapelak B (2016) Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome. Pol Arch Med Wewn 126:579–581PubMedGoogle Scholar
  18. 18.
    Schulman S, Kearon C Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694CrossRefPubMedGoogle Scholar
  19. 19.
    Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf 42(2):377–381CrossRefGoogle Scholar
  20. 20.
    Ciurus T, Sobczak S, Cichocka-Radwan A, Lelonek M (2015) New oral anticoagulants—a practical guide. Kardiochir Torakochirurgia Pol 12:111–118PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacy, Internal MedicineNYU Langone HealthNew YorkUSA
  2. 2.Department of Pharmacy, Internal Medicine & AnticoagulationNYU Langone HealthNew YorkUSA
  3. 3.Division of Hematology, Department of Medicine, Antithrombotic Therapy TeamNYU Langone HealthNew YorkUSA

Personalised recommendations